68-GaNOTA-Anti-HER2 VHH1

N/A

Report date: 2025/09/10 20:01:13

NME

Base Information

Drug Name68-GaNOTA-Anti-HER2 VHH1

Drug Alias Name68GaNOTA-Anti-HER2 VHH1

ClassificationRadiation-emitting products > Nuclides > Gallium > 68GaRadiation-emitting products > Radionuclide Drug ConjugatesRadiation-emitting products > Radioactive diagnostic agent +[4]

Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 modulators

TargetsReceptor protein-tyrosine kinase erbB-2

Therapy Area/IndicationsMetastatic breast cancerProstatic NeoplasmsEndometrial Neoplasms +[14]

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryBelgium

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesUniversitair Ziekenhuis Brussel

China Registration ClassN/A

Develop Information

Active CompaniesUniversitair Ziekenhuis Brussel

Inactive CompaniesN/A

Active IndicationsMetastatic breast cancerProstatic NeoplasmsEndometrial Neoplasms +[14]

Inactive IndicationsN/A

Other Information

ATC CodeN/A